心室辅助装置治疗大动脉转位后体循环右心室衰竭:三尖瓣置换的作用
单中心回顾性研究纳入2010至2019年18例因体循环右心室衰竭植入HeartWare心室辅助装置的成年患者,2017年起常规同期行三尖瓣置换。装置植入技术可行,1年生存率72.2%,植入后跨肺压梯度从16(15-22)降至10(7-13)mmHg(P=0.01),同期三尖瓣置换组(n=6)平均肺动脉压和楔压降低,肺动脉下左心室舒张末内径(44.3 vs 39.6 mm;P=0.03)及功能改善。
要点
- 83.3%患者存在中度或重度体循环三尖瓣反流,88.9%存在肺动脉下左心室功能受损。
- 心室辅助装置植入后跨肺压梯度从16(15-22)降至10(7-13)mmHg(P=0.01)。
- 同期三尖瓣置换组(n=6)肺动脉下左心室舒张末内径44.3 vs 39.6 mm(P=0.03),功能改善。
核心结论
- 心室辅助装置是终末期体循环右心室衰竭患者作为移植候选资格桥接和移植桥接的有效策略。
- 植入时同期行三尖瓣置换与心室辅助装置植入后更好的早期血流动力学和超声心动图结果相关。
研究设计与样本
- 单中心回顾性研究,纳入2010年至2019年连续接受HeartWare心室辅助装置治疗体循环右心室衰竭的成年患者,共18例。
- 自2017年起常规同期行三尖瓣置换。
主要发现
- 83.3%患者存在中度或重度体循环三尖瓣反流,88.9%存在肺动脉下左心室功能受损。
- 1年生存率为72.2%。
- 心室辅助装置植入技术可行且成功,除1例外。
- 植入后跨肺压梯度从16(15-22)降至10(7-13)mmHg(P=0.01)。
- 三尖瓣置换组(n=6)平均肺动脉压和楔压降低,肺动脉下左心室舒张末内径(44.3 vs 39.6 mm;P=0.03)及功能改善;支持1年后72.2%患者适合移植。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Ventricular assist device (VAD) for systemic right ventricular (RV) failure patients post-atrial switch, for transposition of the great arteries (TGA), and those with congenitally corrected TGA has proven useful to reduce transpulmonary gradient and bridge-to-transplantation. The purpose of this study is to describe our experience of VAD in systemic RV failure and our move towards concomitant tricuspid valve replacement (TVR). METHODS: This is a single-centre retrospective study of consecutive adult patients receiving HeartWare VAD for systemic RV failure between 2010 and 2019. From 2017, concomitant TVR was performed routinely. Demographic, clinical variables and echocardiographic and haemodynamic measurements pre- and post-VAD implantation were recorded. Complications on support, heart transplantation and survival rates were described. RESULTS: Eighteen patients underwent VAD implantation. Moderate or severe systemic tricuspid regurgitation was present in 83.3% of patients, and subpulmonic left ventricular impairment in 88.9%. One-year survival was 72.2%. VAD implantation was technically feasible and successful in all but one. Post-VAD, transpulmonary gradient fell from 16 (15-22) to 10 (7-13) mmHg (P = 0.01). Patients with TVR (n = 6) also demonstrated a reduction in mean pulmonary and wedge pressures. Furthermore, subpulmonic left ventricular end-diastolic dimension (44.3 vs 39.6 mm; P = 0.03) and function improved in this group. After 1 year of support, 72.2% of patients were suitable for transplantation. CONCLUSIONS: VAD is an effective strategy as bridge-to-candidacy and bridge-to-transplantation in patients with end-stage systemic RV failure. Concomitant TVR at the time of implant is associated with better early haemodynamic and echocardiographic results post-VAD.
引用
- Gonzalez-Fernandez O, De Rita F, Coats L, et al. Ventricular assist devices in transposition and failing systemic right ventricle: role of tricuspid valve replacement. Eur J Cardiothorac Surg. 2022. PMID: 35244691. doi:10.1093/ejcts/ezac130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。